Amgen Ventures, the venture capital division of Thousand Oaks biotech Amgen Inc., recently invested in Tizona Therapeutics Inc., in both its Series A and Series B rounds. The San Francisco immunology company announced on Tuesday that it had completed its Series B funding, which raised $43 million. The round brought its total capital investment to more than $70 million. The money will be used toward advancing the company’s immunotherapy programs, which include its primary drug candidate for cancer treatment, an anti-CCR4 monoclonal antibody. The Series B financing was led by Abingworth in London and Canaan Partners in Westport, Conn. Other investors include Lightstone Ventures in Menlo Park and MPM Capital in Boston. Amgen shares closed up $3.54 or 2.5 percent to $144.57 on the Nasdaq.
